2910 Seventh Street
50 articles with XOMA
XOMA Corporation reported its second quarter 2021 financial results and provided a recent operations update.
XOMA Acquires Royalty and Milestone Interest in Checkmate’s Vidutolimod (CMP-001) from Kuros Biosciences
XOMA Corporation, announced it has acquired the royalty interest position Kuros Biosciences holds in Checkmate Pharmaceuticals’ vidutolimod, an advanced-generation Toll-like receptor 9 agonist packaged in a virus-like particle, for $7.0 million upfront plus sales milestones.
XOMA Corporation today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:
XOMA Corporation (Nasdaq: XOMA) recently learned its licensees are presenting at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is being held June 4-8, 2021, in a virtual setting.
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $0.5 million milestone from Janssen Biotech, Inc. (Janssen), as a result of the first patient dosed in a Phase 3 clinical trial evaluating one of Janssen’s biologic assets.
XOMA Corporation announced its portfolio of potential future milestone and royalty assets has increased with the addition of three Affimed N.V. innate cell engager programs for which XOMA could receive future economics.
Raised aggregate gross proceeds of $40 million Depositary shares represent an interest in 8.375% Series B Cumulative Perpetual Preferred Stock
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced an underwritten registered public offering of depositary shares, each representing 1/1000 th fractional interest in a share of the Company’s Series B Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per depositary share, subject to market and certain other conditions. The Company expects to grant the underwriters a 30-day
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors approved a dividend of $0.71875 per share to holders of XOMA’s Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP).
Recognized revenue of $29.4 million Six assets in the Company’s milestone and royalty portfolio advanced to Phase 2 clinical development Completed $24.6 million Series A Perpetual Preferred Stock offering paying a 8.625% dividend Ended 2020 with $84.2 million in cash
XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at the following upcoming investor conferences
XOMA Corporation announced its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences:
XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced underwritten registered public offering of 984,000 shares, which includes the underwriters option to purchase additional 104,000 shares of its 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share (the “Preferred Stock”), at an initial public offering price of $25.00 per share. The
XOMA Corporation announced the pricing of its underwritten registered public offering of 880,000 shares of 8.625% Series A Cumulative Perpetual Preferred Stock, with liquidation preference of $25.00 per share at an initial public offering price of $25.00 per share, raising gross proceeds of $22.0 million before deducting underwriting discounts, the structuring fee and other estimated offering expenses.
XOMA Corporation announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab in participants with generalized myasthenia gravis.
XOMA Corporation announced it has earned a $1 million milestone payment from Agenus Inc. related to Merck’s advancement of MK-4830 into a Phase 2 study in patients with advanced non-small cell lung cancer previously treated with anti-programmed cell death receptor ligand 1 therapy.
XOMA Highlights Recent Royalty Asset Portfolio Developments and Reports Third Quarter 2020 Financial Results
Company recently earned a $ 25 million milestone payment as NIS793 advanced to Phase 2 development in advanced pancreatic cancer An u ndisclosed partner entered Phase 2 development, triggering a $0.5 million milestone Rezolute’s financing resulted in accelerated $1.4 million payment Two partners presented early stage data at scientific conferences Acquired royalty interest in four lysosomal storage disorder enzymes being developed by Chiesi Group
In an unrelated development, apartnerinitiated Phase 2 development of an undisclosed asset, which triggers $0.5 million milestone payment to XOMA
XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at two upcoming investor conferences: H.C. Wainwright 22 nd Annual Global Investment Conference. The presentation will take place on Monday, September 14, 2020, at 2:00 PM ET. Cantor Fitzgerald Virtual Global Healthcare Conference. The presentation will take place on Tuesday, September 15, 2020, at 4:00 PM ET. Live webcasts of each
XOMA Reports Second Quarter 2020 Financial ResultsPartners continue to advance clinical assets within the XOMA milestone and royalty portfolio, despite COVID-19-related clinical impacts
XOMA Corporation, announced its second quarter 2020 royalty asset portfolio advancements and financial results.